Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
A phase 2 trial of Tusamitamab ravtansine, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.
Overview
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC is a phase 2 interventional study registered as NCT04524689 by Sanofi, with 57 participants recorded, started 2020-10-26 and due to reach its primary completion in 2024-03-12. Interventions recorded: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed. Conditions recorded: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC).
Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Shares Tusamitamab ravtansine, Sanofi, Non-small-cell lung cancer and the tag pipeline.
- TrialTusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialLDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.